One of the areas of prenatal care that receives significant attention for women pregnant after 35 is genetic testing. The range of options has expanded considerably in recent years, and navigating the landscape of screening versus diagnostic tests, voluntary versus recommended procedures, and what different results might mean can feel overwhelming. Having a clear understanding of what’s available—and what each test does and doesn’t tell you—can support more informed conversations with your healthcare provider.
It’s important to note upfront that prenatal genetic testing is a personal decision, and no test is mandatory. Different families have different values, circumstances, and decision-making frameworks around this area. The goal of this article is to provide information about common tests and what research says about them, not to advocate for any particular choice.
Why Genetic Testing Is Often Discussed More After 35
The association between maternal age and certain chromosomal conditions—most notably trisomy 21 (Down syndrome)—is well-established in the research literature. According to the American College of Obstetricians and Gynecologists (ACOG), the likelihood of a fetus having a chromosomal condition increases gradually with maternal age. However, it’s equally important to understand that the majority of pregnancies after 35 result in chromosomally typical babies—and that chromosomal variations can occur at any age.
Previously, amniocentesis was routinely offered to all women over 35 due to this increased risk. Current guidelines from ACOG indicate that all pregnant women, regardless of age, should be offered both screening and diagnostic testing options, with the choice guided by individual values and informed by non-directive counseling from their healthcare provider.
Screening Tests: Assessing Probability, Not Diagnosis
Screening tests assess the statistical probability that certain chromosomal conditions may be present—they do not provide definitive answers. A screening test cannot confirm or rule out a condition; it provides a risk estimate. This distinction is crucial for interpreting results without unnecessary alarm.
Cell-Free DNA Screening (cfDNA / NIPT)
Cell-free DNA screening—often referred to as non-invasive prenatal testing or NIPT—analyzes fragments of placental DNA present in the maternal bloodstream. It can assess risk for trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), and sex chromosome conditions. Research indicates that cfDNA screening has high sensitivity for trisomy 21—detecting a high proportion of affected pregnancies—and a low false-positive rate compared with traditional screening methods. However, it remains a screening test: positive results should be confirmed with diagnostic testing before any decisions are made, and false positives do occur, particularly for less common conditions. cfDNA screening can typically be performed from around 10 weeks of pregnancy.
First-Trimester Combined Screening
The first-trimester combined screen combines a nuchal translucency ultrasound measurement (assessing fluid at the back of the fetal neck) with blood tests measuring two hormones (PAPP-A and free beta-hCG). Together, these provide a risk estimate for trisomy 21 and trisomy 18. This screen is typically performed between 11 and 14 weeks. As a screening test, it produces a probability rather than a definitive answer, and results outside the reference range do not indicate that a condition is present.
Second-Trimester Serum Screening
Sometimes called the quad screen or triple screen, this blood test offered in the second trimester (typically 15–20 weeks) measures several hormones and proteins to assess risk for trisomy 21, trisomy 18, and open neural tube defects. It may be offered as a standalone screening or as part of integrated or sequential screening protocols that combine first and second-trimester results.
Diagnostic Tests: Definitive Results With Associated Considerations
Diagnostic tests—chorionic villus sampling (CVS) and amniocentesis—provide a definitive chromosomal analysis of the pregnancy. They can confirm or rule out chromosomal conditions with high accuracy. Both involve obtaining a small sample of tissue (placental for CVS, amniotic fluid for amniocentesis) and come with a small but real risk of pregnancy loss. Research suggests that this risk is low and has declined with improvements in technique and technology, but it is part of the informed consent discussion that should accompany these procedures. A genetic counselor can provide detailed, individualized information about what these tests involve and what results might mean for your specific situation.
The Role of Genetic Counseling
Genetic counseling is a resource available to all pregnant women, and is particularly valuable for those navigating testing decisions. A certified genetic counselor can help you understand which tests are available and what they measure, interpret screening results in the context of your individual risk profile, discuss the implications of diagnostic test results, and explore the range of choices and support options available depending on outcomes.
Many women find that speaking with a genetic counselor before making testing decisions—rather than after receiving an unexpected result—helps them feel more prepared and less reactive. If your prenatal care provider hasn’t mentioned genetic counseling, asking about a referral is entirely appropriate.
Making Informed Decisions About Testing
There is no universally “right” choice about prenatal genetic testing. Some families want as much information as possible and would use diagnostic results to guide medical decisions or prepare for specific needs. Others prefer not to pursue testing for personal, ethical, or pragmatic reasons. Some choose screening but not diagnostic testing. All of these positions are valid, and the role of your healthcare team is to provide information and support your decision-making process—not to direct a particular choice.
Understanding the difference between a screening probability and a diagnostic result, and what each test does and doesn’t measure, puts you in a stronger position to have these conversations with clarity and confidence.
Frequently Asked Questions
Is amniocentesis routinely recommended for all women over 35?
Current ACOG guidelines indicate that all pregnant women should be offered the option of screening and diagnostic testing, regardless of age—but that no test should be presented as required. Amniocentesis is a diagnostic option, not a routine requirement, for women over 35. The decision about whether to pursue it is personal and should be made with informed, non-directive support from your healthcare provider or genetic counselor.
What does a “high-risk” screening result actually mean?
A high-risk result on a screening test means the statistical probability of a chromosomal condition is above a defined threshold—it does not mean the condition is present. Many pregnancies with high-risk screening results are found to be chromosomally typical on diagnostic testing. Receiving a high-risk screening result is an indication for further evaluation, not a diagnosis.
Can NIPT tell me the sex of my baby?
Yes, NIPT typically identifies fetal sex as part of its analysis of sex chromosomes, and this information can be shared with the family if they choose. Some people prefer not to receive sex information until birth, and this preference can be communicated to the laboratory. Sex determination accuracy through NIPT is generally high after 10 weeks.
What if I want to pursue testing but my partner doesn’t?
Divergent perspectives on genetic testing within a couple are not uncommon, and genetic counselors are experienced at supporting couples in navigating these conversations. Opening a dialogue with a counselor together—before making a decision—can provide a structured, supportive space for working through different perspectives and values.
Key Takeaways
- Prenatal genetic testing options fall into two categories: screening tests (which assess probability) and diagnostic tests (which provide definitive chromosomal information with a small associated risk).
- ACOG currently recommends that all pregnant women be offered both screening and diagnostic testing options, regardless of age—the decision is guided by individual values and informed consent.
- Cell-free DNA screening (NIPT) offers high sensitivity for common chromosomal trisomies and is available from around 10 weeks, though positive screening results should always be confirmed diagnostically before decisions are made.
- Genetic counseling is a valuable resource for understanding options, interpreting results, and making decisions aligned with your values—referrals can be requested from your prenatal care provider.
- No testing choice is universally right; the goal is informed decision-making that aligns with your individual circumstances and values.
Medical Disclaimer
This content is for informational purposes only and does not constitute medical advice. Individual health situations vary significantly. Always consult a qualified healthcare provider before making decisions related to your health, fertility, or pregnancy.
About the Author
Emily Carter is a women’s health writer focused on fertility, pregnancy after 35, and sleep changes in midlife. She writes research-informed, non-alarmist content to help women navigate reproductive and hormonal transitions with clarity and confidence.